SciNeuro is developing antisense oligonucleotides and monoclonal antibodies to target specific proteins associated with neurodegenerative diseases, such as LRRK2 in Parkinson's disease and alpha-synuclein in synucleinopathies. The company aims to provide disease-modifying therapies that address the underlying mechanisms of these conditions, moving beyond current symptomatic treatments.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LAFounders
Product
Problem
Neurodegenerative diseases like Parkinson's, Alzheimer's, ALS, and frontotemporal dementia lack effective treatments that address the underlying disease mechanisms. Current therapies primarily focus on managing symptoms rather than halting or reversing disease progression. This leaves a significant unmet need for disease-modifying interventions.
Solution
SciNeuro is developing a pipeline of therapeutics, including antisense oligonucleotides (ASOs) and monoclonal antibodies, designed to target specific proteins implicated in neurodegenerative disorders. Their approach aims to modulate the expression or activity of key proteins, such as LRRK2, alpha-synuclein, Lp-PLA2, and TDP-43, to slow or prevent disease progression. By focusing on the root causes of these conditions, SciNeuro seeks to provide more effective and durable treatments compared to existing symptomatic therapies. Their pipeline includes programs targeting Parkinson's disease, synucleinopathies, Alzheimer's disease, ALS, and certain forms of frontotemporal dementia.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, ALS, and frontotemporal dementia, as well as the healthcare professionals who treat them.
Features
- SNP614: A chemically modified ASO designed to downregulate LRRK2 mRNA, reducing LRRK2 protein levels and activity in Parkinson's disease.
- SNP201: A high-affinity alpha-synuclein antibody that preferentially binds to aggregated forms of alpha-synuclein, targeting a key pathological hallmark of synucleinopathies.
- SNP318: A CNS-penetrant inhibitor of Lp-PLA2, designed to repair the blood-brain barrier and improve cognition in dementias like Alzheimer's disease.
- SNP210: A human autoantibody with high affinity for disease-variant TDP-43, targeting toxic aggregates in ALS and certain forms of frontotemporal dementia.